<?xml version="1.0" encoding="UTF-8"?>
<p id="par0135">In a recent report, 
 <xref rid="bib0145" ref-type="bibr">Kutikov et al. (2020)</xref> proposed some interesting starting points to guide decision making during pandemic on the basis of a risk assessment for cancer treatment delay. Decision regarding surgery, radiotherapy and medical treatment delays are made after a risk-to-benefit evaluation between the risk of cancer progression due to delay (based tumor type and stage of disease) and risk for significant COVID-19 associated morbidity (based on age and presence of comorbidities). Other relevant elements to consider in decision making are the intent of treatment strategy (i.e. curative vs non-curative), and the patientsâ€™ life expectancy (
 <xref rid="bib0145" ref-type="bibr">Kutikov et al. (2020)</xref>).
</p>
